Table 2.
Comparison of patients interrupting and not interrupting OMZ treatment.
| General characteristics (n = 103) | OMZ interrupted (n = 17) (%) | OMZ not interrupted (n = 86) (%) | P |
|---|---|---|---|
| Gender | 1.000a | ||
| Female | 12 (16.9) | 59 (83.1) | |
| Male | 5 (15.6) | 27 (84.4) | |
| Comorbidities | 0.748a | ||
| (+) | 6 (14) | 37 (86) | |
| (−) | 11 (18.3) | 49 (81.7) | |
| Duration of OMZ usage | 0.005a | ||
| ≤ 6 months | 1 (2.5) | 39 (97.5) | |
| > 6 months | 16 (25.4) | 47 (74.6) | |
| COVID-19 history | 0.698b | ||
| (+) | 3 (17.6) | 11 (12.8) | |
| (−) | 14 (82.4) | 75 (87.2) |
COVID-19: coronavirus disease-19; OMZ: omalizumab.
a
Continuity correction.
b
Fisher's exact test.